Ask me later

Ask me later

How likely are you to recommend Redeye to a friend or colleague?

1

2

3

4

5

6

7

8

9

10

Not likely

Very likely

Not likely

1

2

3

4

5

6

7

8

9

10

Very likely

Message received

Thanks again for rating us!

Alzinova: Short comment on yesterday’s aducanumab news

2021-11-18

09:19

KS

Kevin Sule

Redeye leaves a short comment on the EMA’s negative trend vote on Biogen’s aducanumab and what it means for Alzinova.

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers